Quetiapine Fumarate is an atypical antipsychotic indicated for schizophrenia, bipolar disorder and, as extended release, adjunctive treatment of major depressive disorder. We supply it to US manufacturers of tablets and extended-release tablets.
Data from PubChem (CID 5281025) and FDA’s substance registry
CAS number
111974-72-2
Molecular formula
C46H54N6O8S2
Molecular weight
883.1g/mol
FDA UNII
IUPAC name
bis(2-[2-(4-benzo[b][1,4]benzothiazepin-6-ylpiperazin-1-yl)ethoxy]ethanol);(E)-but-2-enedioic acid
InChIKey
ZTHJULTYCAQOIJ-WXXKFALUSA-N
- Appearance
- White to off-white crystalline powder.
- Solubility
- Moderately soluble in water.
Typical description, from FDA-approved labeling and pharmacopoeial monographs. The specification sent with your quote is the controlling document for any source.
Worth settling with your inquiry
Supplied as the hemifumarate, two quetiapine molecules to one of fumaric acid. Strengths are expressed as quetiapine base.
On the US market
- Reference product
- SeroquelNDA 020639
- Approved ANDAs
- 25 with a marketed product
- Approved forms and strengths
- Tablet 25 mg to 400 mg, in 7 strengths
- Extended-release tablet 50 mg, 150 mg, 200 mg, 300 mg, 400 mg
Single-ingredient products in FDA’s Drugs@FDA database, retrieved November 2026. Strengths of salt forms are stated as the active moiety. The brand name belongs to its owner and identifies the reference product only.
Grade
USP or Ph. Eur. where a monograph exists, or your own specification.
Quantities
From development quantities for formulation work to commercial supply.
Packaging
To the manufacturer’s standard, typically fiber or HDPE drums with double polyethylene liners.
Regulatory filings
US DMF and CEP availability depends on the source. We confirm the filing status in writing with the quotation.
Documents available with a quote
- Specification and certificate of analysis
- Safety data sheet
- Method of analysis
- DMF letter of authorization, where a US DMF is filed
- GMP certificate and inspection history of the site
- Residual solvents and elemental impurities statements
- Nitrosamine risk assessment
- TSE/BSE statement
Need something else for your QA file? Email info@yogpharma.com
Sertraline Hydrochloride
Selective serotonin reuptake inhibitor (SSRI)
CAS 79559-97-0Escitalopram Oxalate
Selective serotonin reuptake inhibitor (SSRI)
CAS 219861-08-2Duloxetine Hydrochloride
Serotonin-norepinephrine reuptake inhibitor (SNRI)
CAS 136434-34-9Bupropion Hydrochloride
Norepinephrine-dopamine reuptake inhibitor
CAS 31677-93-7